Kala Bio (KALA) Change in Receivables (2019 - 2023)
Kala Bio (KALA) posted Change in Receivables of $2000.0 for Q2 2023, up 102.5% sequentially from -$80000.0 in Q1 2023, and down 99.75% YoY from $802000.0 in Q2 2022.
Kala Bio (KALA) Change in Receivables (2019 - 2023) Analysis & Trends
Kala Bio has reported Change in Receivables for 5 years, with the latest figure at $2000.0 in Q2 2023.
- Quarterly Change in Receivables fell 99.75% year-over-year to $2000.0 in Q2 2023, while the trailing twelve-month figure through Dec 2023 was -$78000.0 (up 99.48% YoY) and the FY2023 annual result came in at -$78000.0, up 99.48% from the prior year.
- Change in Receivables climbed to $2000.0 in Q2 2023 per KALA's latest filing, from -$80000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $4.7 million in Q1 2019 and troughed at -$13.6 million in Q3 2022.
- A 5-year average of $8000.0 and a median of $786500.0 in 2021 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 331.12% in 2022, down 1866.54% in 2022.
- Over 5 years, Change in Receivables stood at $4.4 million in 2019, then sank by 51.07% to $2.1 million in 2020, then gained by 27.04% to $2.7 million in 2021, then tumbled by 99.82% to $5000.0 in 2022, then slumped by 60.0% to $2000.0 in 2023.
- According to Business Quant data, Change in Receivables over the past three periods registered $2000.0, -$80000.0, and $5000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | -80,000.00 |
| Mar 31, 2023 | -80,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Dec 31, 2022 | 5,000.00 |
| Sep 30, 2022 | -13.62 Mn |
| Sep 30, 2022 | -13.62 Mn |
| Jun 30, 2022 | 802,000.00 |
| Jun 30, 2022 | 802,000.00 |
| Mar 31, 2022 | -2.33 Mn |
| Mar 31, 2022 | -2.33 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Sep 30, 2021 | 771,000.00 |
| Sep 30, 2021 | 771,000.00 |
| Jun 30, 2021 | -347,000.00 |
| Jun 30, 2021 | -347,000.00 |
| Mar 31, 2021 | 2.60 Mn |
| Mar 31, 2021 | 2.60 Mn |